Please ensure Javascript is enabled for purposes of website accessibility

Tilray Signs Landmark European Shipment Deal

By Eric Volkman – Aug 22, 2019 at 10:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company will deliver $3.3 million worth of medical cannabis from its facility in Portugal to Germany.

Noted marijuana producer Tilray (TLRY) reported some news of note. On Wednesday, the company announced that it has signed a deal to ship marijuana from its growth and shipment facility in Portugal. The deal, signed with privately held German medical cannabis importer Cannamedical Pharma, is for $3.3 million worth of medical product. This will be transported from the facility to Germany.

Tilray said that it expects to complete this shipment in the fall.

In the press release trumpeting the arrangement, Tilray pointed out that it is the first such contract it's signed to ship product from the Portugal facility to Germany. The latter country is considered a key European market due to its size and its booming market for medical cannabis (recreational use is not permitted -- at least not yet).

The company said in the press release that "[t]his is a significant milestone for Tilray as we ramp up our capacity to serve international markets and generate revenue from our EU campus through the end of 2019. ... We believe our 2.5 million square feet of cultivation and state-of-the-art processing space in Europe is an important differentiator, which will enable us to reduce costs and improve margins while hedging against regulatory risk."

Marijuana in a corporate grow space.

Image source: Getty Images.

The Portugal facility is a cornerstone international asset for Tilray, which, like many large North American cannabis companies, has global ambitions. It received a license to grow, import, and export bulk medical marijuana in Portugal in mid-2017, and its first harvest at the facility was completed this past February.

Tilray believes that Germany's legalization of medical marijuana will be replicated throughout the EU, which currently has 28 member states. Earlier this month, one of those nations, Luxembourg, said it will soon roll out legislation to sanction all forms of cannabis production and use within its borders (although the legalization process will likely take several years to enact). The country already allows cannabis for medical use.

Tilray's partner in the Germany deal, Cannamedical, was quoted in the press release as saying that "Tilray's product has passed our strict quality control standards, and we're excited to have found a partner able to deliver medical cannabis products for use in Cannamedical's own brands."

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote
Tilray
TLRY

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.